KR100766273B1 - 아디포넥틴을 유효 성분으로 포함하는 프라더-윌리 증후군소아용 수면 장애 치료제 - Google Patents
아디포넥틴을 유효 성분으로 포함하는 프라더-윌리 증후군소아용 수면 장애 치료제 Download PDFInfo
- Publication number
- KR100766273B1 KR100766273B1 KR1020060102667A KR20060102667A KR100766273B1 KR 100766273 B1 KR100766273 B1 KR 100766273B1 KR 1020060102667 A KR1020060102667 A KR 1020060102667A KR 20060102667 A KR20060102667 A KR 20060102667A KR 100766273 B1 KR100766273 B1 KR 100766273B1
- Authority
- KR
- South Korea
- Prior art keywords
- sleep
- adiponectin
- prader
- children
- pws
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (3)
- 아디포넥틴을 유효 성분으로 포함한 수면 호흡 장애를 경감시키고 급속 안구운동 수면(REM 수면)을 유도하는 프라더-윌리 증후군 소아용 수면 장애 치료제
- 제 1항에 있어서, 상기 프라더-윌리 증후군 소아용 수면 장애 치료제의 1일 투여량은 0.1∼10 mg/kg 소아체중임을 특징으로 하는 프라더-윌리 증후군 소아용 수면 장애 치료제
- 제 1항에 있어서, 상기 프라더-윌리 증후군 소아용 수면 장애 치료제는 아디포넥틴과 약제학적으로 허용 가능한 담체 및 보조제를 더욱 포함함을 특징으로 하는 프라더-윌리 증후군 소아용 수면 장애 치료제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060102667A KR100766273B1 (ko) | 2006-10-23 | 2006-10-23 | 아디포넥틴을 유효 성분으로 포함하는 프라더-윌리 증후군소아용 수면 장애 치료제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060102667A KR100766273B1 (ko) | 2006-10-23 | 2006-10-23 | 아디포넥틴을 유효 성분으로 포함하는 프라더-윌리 증후군소아용 수면 장애 치료제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060115977A KR20060115977A (ko) | 2006-11-13 |
KR100766273B1 true KR100766273B1 (ko) | 2007-10-15 |
Family
ID=37653114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060102667A KR100766273B1 (ko) | 2006-10-23 | 2006-10-23 | 아디포넥틴을 유효 성분으로 포함하는 프라더-윌리 증후군소아용 수면 장애 치료제 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100766273B1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5432567B2 (ja) * | 2008-04-16 | 2014-03-05 | 花王株式会社 | アディポネクチン分泌調節剤の評価又は選択方法 |
CA2753876A1 (en) * | 2009-03-20 | 2010-09-23 | The Salk Institute For Biological Studies | Methods for modulating circadian rhythms |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH039900A (ja) * | 1989-06-06 | 1991-01-17 | Dainippon Printing Co Ltd | 転写箔の製造方法 |
-
2006
- 2006-10-23 KR KR1020060102667A patent/KR100766273B1/ko active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH039900A (ja) * | 1989-06-06 | 1991-01-17 | Dainippon Printing Co Ltd | 転写箔の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20060115977A (ko) | 2006-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tatsumi et al. | Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea-hypopnea syndrome | |
Shimura et al. | Fat accumulation, leptin, and hypercapnia in obstructive sleep apnea-hypopnea syndrome | |
García-Río et al. | Sleep apnea and hypertension | |
Devouassoux et al. | Sleep apnea is associated with bronchial inflammation and continuous positive airway pressure–induced airway hyperresponsiveness | |
Garcia et al. | Weight and metabolic effects of CPAP in obstructive sleep apnea patients with obesity | |
Burgos et al. | Increased nocturnal interleukin-6 excretion in patients with primary insomnia: a pilot study | |
Fredheim et al. | Type 2 diabetes and pre-diabetes are associated with obstructive sleep apnea in extremely obese subjects: a cross-sectional study | |
Marcus et al. | Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age | |
Vgontzas et al. | Selective effects of CPAP on sleep apnoea‐associated manifestations | |
Edwards et al. | Obstructive sleep apnea and neurocognitive performance: the role of cortisol | |
Yuan et al. | Ventilatory responses to hypercapnia during wakefulness and sleep in obese adolescents with and without obstructive sleep apnea syndrome | |
Toi et al. | Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus | |
Guo et al. | Effect of continuous positive airway pressure therapy on glycemic excursions and insulin sensitivity in patients with obstructive sleep apnea-hypopnea syndrome and type 2 diabetes | |
Stege et al. | Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD | |
Hui et al. | Nocturnal hypoxemia causes hyperglycemia in patients with obstructive sleep apnea and type 2 diabetes mellitus | |
Sipilä et al. | Long‐term effects of growth hormone therapy on patients with Prader–Willi syndrome | |
Slusher et al. | Brain‐derived neurotrophic factor and substrate utilization following acute aerobic exercise in obese individuals | |
Azuma et al. | Association between endothelial function (assessed on reactive hyperemia peripheral arterial tonometry) and obstructive sleep apnea, visceral fat accumulation, and serum adiponectin | |
Otake et al. | Glucose intolerance in Japanese patients with obstructive sleep apnea | |
Sánchez-De-La-Torre et al. | Plasma levels of neuropeptides and metabolic hormones, and sleepiness in obstructive sleep apnea | |
Kanezaki et al. | Perception of urge-to-cough and dyspnea in healthy smokers with decreased cough reflex sensitivity | |
Papaioannou et al. | Lack of association between impaired glucose tolerance and appetite regulating hormones in patients with obstructive sleep apnea | |
Chen et al. | Relationship between serum adiponectin and bone mineral density in male patients with obstructive sleep apnea syndrome | |
Araz et al. | Is there a relationship between obstructive sleep apnea syndrome severity and nesfatin-1? | |
KR100766273B1 (ko) | 아디포넥틴을 유효 성분으로 포함하는 프라더-윌리 증후군소아용 수면 장애 치료제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121004 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130910 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140911 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151005 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20181004 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20191002 Year of fee payment: 13 |